| Literature DB >> 32122407 |
Yingying Wang1, Jialing Lin2, Junli Zhou1, Zhigang Han3, Zhenjiang Yao4.
Abstract
BACKGROUND: Staphylococcus aureus (S. aureus), particularly methicillin-resistant Staphylococcus aureus (MRSA), remains the predominant cause of infections in drug users. This cross-sectional study aims to elucidate the prevalence, risk factors, phenotypic and molecular characteristics of S. aureus carriage among community-based drug users.Entities:
Keywords: Antimicrobial susceptibility; Drug user; MRSA; Molecular characteristics; Risk factor; S. aureus
Mesh:
Substances:
Year: 2020 PMID: 32122407 PMCID: PMC7053115 DOI: 10.1186/s13756-020-0698-9
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Univariate analysis of risk factor for S. aureus carriage among drug users in Guangzhou, China, 2017
| Characteristics | Non- | ||
|---|---|---|---|
| Demographics-level | |||
| Sex (Male) | 262 (87.33) | 47 (88.68) | 0.784 |
| age (> 50) | 169 (56.33) | 26 (49.06) | 0.326 |
| Social-level | |||
| Current employed (Yes) | 80 (26.67) | 14 (26.42) | 0.970 |
| Current cohabitataion (Yes) | 3 (1.00) | 4 (7.55) | 0.011 |
| Low income (Yes) | 61 (20.33) | 17 (32.08) | 0.058 |
| History of homelessness in past 6 months (Yes) | 9 (3.00) | 3 (5.66) | 0.400 |
| History of incarceration (Yes) | 240 (80.00) | 44 (83.02) | 0.609 |
| Behavior-level | |||
| History of vaginal sex in past 1 month (Yes) | 97 (33.68) | 13 (26.53) | 0.324 |
| Number of sexual partners in past 1 year (> 1) | 28 (9.33) | 2 (3.77) | 0.283 |
| Health-level | |||
| Current HIV positive (Yes) | 22 (7.33) | 2 (3.77) | 0.553 |
| Current hepatitis (Yes) | 114 (38.00) | 24 (45.28) | 0.316 |
| Antibiotic use in past 6 months (Yes) | 83 (27.67) | 16 (30.19) | 0.706 |
| History of hospitalization in past 1 year (Yes) | 32 (10.67) | 9 (16.98) | 0.186 |
| History of skin infection in past 6 months (Yes) | 130 (43.33) | 25 (47.17) | 0.604 |
| History of needle exchange in past 1 year (Yes) | 26 (8.67) | 4 (7.55) | 1.000 |
| Drug use-level | |||
| Period of drug use (> 10 years) | 18 (6.00) | 0 (0.00) | 0.087 |
| History of heroin snorting in past 3 months (Yes) | 188 (62.67) | 41 (77.36) | 0.039 |
| History of intravenous heroin in past 3 months (Yes) | 113 (37.67) | 14 (26.42) | 0.116 |
| History of using injection drugs in past 3 months (Yes) | 187 (62.33) | 39 (73.58) | 0.116 |
S. aureus Staphylococcus aureus; N Number of total participants; HIV Human immunodeficiency virus
Fig. 1Multivariate analysis of risk factors for S. aureus carriage among community-based drug users in Guangzhou, China, 2017. S. aureus, Staphylococcus aureus; No., Number of; OR, Odds ratio; CI, Confidence interval; HIV, Human immunodeficiency virus
Phenotypic and molecular characteristics of S. aureus isolates among drug users in Guangzhou, China, 2017
| Characteristics | |||
|---|---|---|---|
| Total | MRSA( | MSSA ( | |
| Resistant phenotype (resistant) | |||
| Clindamycin | 24 (45.28) | 15 (62.50) | 9 (31.03) |
| Erythromycin | 26 (49.06) | 15 (62.50) | 11 (37.93) |
| Penicillin | 49 (92.45) | 23 (95.83) | 26 (89.66) |
| Linezolid | 1 (1.89) | 1 (4.17) | 0 (0.00) |
| Gentamicin | 4 (7.55) | 3 (12.50) | 1 (3.45) |
| Teicoplanin | 10 (18.87) | 8 (33.33) | 2 (6.90) |
| Trimethoprim-sulfamethoxazole | 7 (13.21) | 4 (16.67) | 3 (10.34) |
| Moxifloxacin | 5 (9.43) | 4 (16.67) | 1 (3.45) |
| Rifampin | 2 (3.77) | 2 (8.33) | 0 (0.00) |
| Chloramphenicol | 11 (20.75) | 7 (29.17) | 4 (13.79) |
| Tetracycline | 17 (32.08) | 9 (37.50) | 8 (27.59) |
| Resistant genotype (positive) | |||
| | 1 (1.89) | 1 (4.17) | 0 (0.00) |
| | 5 (9.43) | 5 (20.83) | 0 (0.00) |
| | 4 (7.55) | 4 (16.67) | 0 (0.00) |
| | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Virulence genes (positive) | |||
| | 3 (5.66) | 3 (12.50) | 0 (0.00) |
| | 2 (3.77) | 2 (8.33) | 0 (0.00) |
| | 1 (1.89) | 1 (4.17) | 0 (0.00) |
| | 1 (1.89) | 1 (4.17) | 0 (0.00) |
| | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| | 1 (1.89) | 0 (0.00) | 1 (3.45) |
| | 3 (5.66) | 1 (4.17) | 2 (6.90) |
| | 17 (32.08) | 11 (45.83) | 6 (20.69) |
| | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| | 26 (49.06) | 13 (54.17) | 13 (44.83) |
| | 3 (3.45) | 3 (12.50) | 0 (0.00) |
| | 18 (33.96) | 9 (37.50) | 9 (31.03) |
| | 6 (11.32) | 3 (12.50) | 3 (10.34) |
| | 11 (20.75) | 8 (33.33) | 3 (10.34) |
| | 4 (7.55) | 2 (8.33) | 2 (6.90) |
| | 16 (30.19) | 6 (25.00) | 10 (34.48) |
| | 12 (22.64) | 4 (16.67) | 8 (27.59) |
| | 13 (24.53) | 4 (16.67) | 9 (31.03) |
| | 4 (7.55) | 1 (4.17) | 3 (10.34) |
| | 5 (9.43) | 2 (8.33) | 3 (10.34) |
| | 5 (9.43) | 2 (8.33) | 3 (10.34) |
| | 12 (22.64) | 7 (29.17) | 5 (17.24) |
S. aureus Staphylococcus aureus; MRSA Methicillin-resistant S. aureus; MSSA Methicillin- sensitive S. aureus
Fig. 2Clonal dendrogram and detailed information of S. aureus isolates for community-based drug users in Guangzhou, China, 2017. Isolates with the same color represented they were from the same community; squares represented MRSA isolates and circles represented MSSA isolates. S. aureus, Staphylococcus aureus; MRSA, Methicillin-resistant S. aureus; MSSA, Methicillin- sensitive S. aureus; ST, Sequence type; SCCmec, Staphylococcal cassette chromosome mec; MDR, Multidrug resistance; P, Penicillin; E, Erythromycin; DA, Clindamycin; TE, Tetracycline; C, Chloramphenicol; SXT, Trimethoprim-sulfamethoxazole; TEC, Teicoplanin; MXF, Moxifloxacin; CN, Gentamicin; RD, Rifampin; LZD, Linezolid